First-pass extracted concept

in vivo CAR-T cell engineering

Candidate: concept label1 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

In vivo CAR-T cell engineering offers a transformative alternative by reprogramming endogenous T cells within the patient, bypassing the need for cell harvesting and expansion.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1approach descriptionsupports2026Source 1DOI PubMed

In vivo CAR-T cell engineering reprograms endogenous T cells within the patient and bypasses cell harvesting and expansion.

Claim 2challenge statementsupports2026Source 1DOI PubMed

Key delivery-related optimization goals for in vivo CAR-T therapy include improving vector stability, enhancing T-cell targeting, and reducing immunogenicity.

Claim 3design principlesupports2026Source 1DOI PubMed

Vector tropism, membrane modifications, and targeting ligands are design principles used in in vivo CAR-T delivery strategies.

Claim 4problem statementsupports2026Source 1DOI PubMed

Conventional ex vivo CAR-T manufacturing is costly, individualized, and logistically complex, limiting accessibility and scalability.

Claim 5therapeutic contextsupports2026Source 1DOI PubMed

CAR-T cell therapy enables potent antigen-specific immune responses and has demonstrated success in treating hematologic malignancies.